Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04017130 is registered in ClinicalTrials.gov with Molecular Templates, Inc. as lead sponsor.

NCT NCT04017130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04017130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Molecular Templates, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 5, 2020
Completion date
December 13, 2023
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma